• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2009 Fiscal Year Final Research Report

Study for regulatory mechanism of normal and leukemic stem cells through transcription factors

Research Project

  • PDF
Project/Area Number 19390268
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Research Field Hematology
Research InstitutionNational Cancer Center Research Institute and Research Center for Innovative Oncology, National Cancer Center Hospital East

Principal Investigator

KITABAYASHI Issay  National Cancer Center Research Institute and Research Center for Innovative Oncology, National Cancer Center Hospital East, 分子腫瘍学部, 部長 (20261175)

Co-Investigator(Kenkyū-buntansha) YAMAGATA Kazutsune  国立がんセンター(研究所及び東病院臨床開発センター), 分子腫瘍学部, 研究員 (70311412)
ROKUDAI Susumu  国立がんセンター(研究所及び東病院臨床開発センター), 分子腫瘍学部, 研究員 (50469970)
YOSHIDA Hitoshi  国立がんセンター(研究所及び東病院臨床開発センター), 分子腫瘍学部, 室長 (10506710)
WATANABE Toshio  奈良女子大学, 大学院・人間文化研究科, 教授 (60201208)
Project Period (FY) 2007 – 2009
Keywords幹細胞 / 白血病 / 転写制御
Research Abstract

MOZ (MOnocytic leukemia Zinc finger protein) and MORF (MOz Related Factor), Myst-type histone acetyltransferases, are involved in chromosome translocations associated with FAB-M4/5 subtypes of acute myeloid leukemia. We have reported that MOZ is essential for hematopoietic cell development and self-renewal of hematopoietic stem cells. To elucidate the roles of MORF in normal and malignant hematopoiesis, we generated Morf-deficient mice. Morf--/- mice were smaller than their wild-type littermates and died within 4 weeks after birth. In Morf--/- fetal liver, Flt3-negative KSL (c-Kit+, Sca-1+, Lineage-) cells containing hematopoietic stem cells are decreased. When fetal liver cells were transplanted into irradiated recipient mice, MORF-/- cells less efficiently reconstituted hematopoiesis than wild-type cells. Additionally, bone marrow cells reconstituted with MORF-/- cells rarely contributed to hematopoiesis in secondary transplants. To reveal interaction between MORF and MOZ, we generated double heterozygous (Moz+/- Morf+/-) mouse. Double heterozygous mouse was also smaller than wild-type littermates and died at least 4 weeks after birth. Numbers of KSL cells, especially Flt3- KSL cells and common myeloid progenitors were decreased in the double heterozygous fetal liver. The double heterozygous fetal liver cells also displayed less activity to reconstitute hematopoiesis than MOZ+/- or MORF+/- cells. These results suggest that MORF as well as MOZ plays important roles in self-renewal of hematopoietic stem cells.

  • Research Products

    (18 results)

All 2010 2009 2008 2007

All Journal Article (10 results) Presentation (6 results) Patent(Industrial Property Rights) (2 results)

  • [Journal Article] A Higher-Order Complex Containing AF4 and ENL Family Proteins with P-TEFb Facilitates Oncogenic and Physiologic MLL-Dependent Transcription.2010

    • Author(s)
      Yokoyama A, Lin M, Naresh A, Kitabayashi I, Cleary ML.
    • Journal Title

      Cancer Cell 17

      Pages: 198-212

  • [Journal Article] 1-mediated upregulation of M-CSFR is critical for leukemia stem cell potential induced by MOZ-TIF2.2010

    • Author(s)
      Aikawa Y, Katsumoto K, Zhang P, Shima H, Shino M, Terui K, Ito E, Ohno H, Stanley ER, Singh H, Tenen DG, Kitabayashi I. PU.
    • Journal Title

      Nat Med 16

      Pages: 580-585

  • [Journal Article] MOZ interacts with p53 to induce p21 expression and cell-cycle arrest.2009

    • Author(s)
      Rokudai S, Aikawa Y, Tagata Y, Tsuchida N, Taya Y, Kitabayashi I.
    • Journal Title

      J Biol Chem. 284

      Pages: 237-244

  • [Journal Article] Sirt1 physically interacts with Tip60 and negatively regulates Tip60-mediated acetylation of H2AX.2009

    • Author(s)
      Yamagata K, Kitabayashi I.
    • Journal Title

      Biochem Biophys Res Commun 390

      Pages: 1355-1360

  • [Journal Article] Phosphorylation of PML is essential for activation of C/EBPe and PU. 1 to accelerate granulocytic differentiation.2008

    • Author(s)
      Tagata Y., Yoshida H, Nguyen LA, Kato H, Ichikawa H, Tashiro F, Kitabayashi I.
    • Journal Title

      Leukemia 22

      Pages: 273-280

  • [Journal Article] Roles of the histone acetyltransferase MOZ in normal and malignant hematopoiesis.2008

    • Author(s)
      Katsumoto T, Yoshida N, Kitabayashi I
    • Journal Title

      Cancer Sci. 99

      Pages: 1523-7

  • [Journal Article] PML activates transcription by protecting HIPK2 and p300 from SCF/Fbx3-mediated degradation.2008

    • Author(s)
      Shima Y, Shima T, Chiba T, Irimura T, Pandolfi PP, Kitabayashi I.
    • Journal Title

      Mol Cell Biol. 28

      Pages: 7126-7138

  • [Journal Article] Foxp3 controls regulatory T cell function via interacting with AML1/Runx1.2007

    • Author(s)
      Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, Miyachi Y, Tsukada T, Sakaguchi, S.
    • Journal Title

      Nature 446

      Pages: 685-689

  • [Journal Article] Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1-and p53-mediated transcription.2007

    • Author(s)
      Li XL, Arai Y, Harada H, Shima Y, Yoshida H, Rokudai S, Aikawa Y, Kimura A, Kitabayashi I.
    • Journal Title

      Oncogene. 26

      Pages: 7231-7239

  • [Journal Article] PML-RARA inhibits PML IV enhancement of PU. 1-induced C/EBPe induced-expression in myeloid differentiation.2007

    • Author(s)
      Yoshida H, Ichikawa H, Tagata Y, Katsumoto T, Ohnishi K, Akao Y, Naoe T, Pandolfi PP, Kitabayashi I.
    • Journal Title

      Mol. Cell. Biol. 27

      Pages: 5819-5834

  • [Presentation] The role of YB-1, a binding partner of nucleophosmin, in hematopoiesis and nucleophosmin mutant (NPMc)-associated acute myeloid leukemia.2010

    • Author(s)
      Yoko Ogawara, Takuo Katsumoto, Takeshi Uchiumi, Kimitoshi Kohno, Issay Kitabayashi
    • Organizer
      2010 AACR/JCR Joint Conference Hilton waikoloa Village in Hawaii
    • Place of Presentation
      USA
    • Year and Date
      20100206-20100210
  • [Presentation] PU. 1-mediated upregulation of M-CSFR is critical for MOZ-leukemia stem cell potential2009

    • Author(s)
      Yukiko Aikawa1, Takuo Katsumoto1, Daniel G Tenen, Issay Kitabayashi1
    • Organizer
      51th annual meeting of American Society of Hemaology Ernest N.
    • Place of Presentation
      Merial Convention Center New Orleans
    • Year and Date
      20091205-20091208
  • [Presentation] Hemizygousity of AML1/RUNX1, a target of p53, prevents T-cell malignancy induced by loss of p532009

    • Author(s)
      Kimiko Shimizu, Issay Kitabayashi
    • Organizer
      Runx Meeting 2009
    • Place of Presentation
      Oxford University
    • Year and Date
      20090816-20090819
  • [Presentation] Roles of histone actyltransferases MOZ/MORF in hematopoiesis and leukemia2009

    • Author(s)
      Yukiko Aikawa, Takuo Katsumoto, Issay Kitabayashi
    • Organizer
      Runx Meeting 2009
    • Place of Presentation
      Oxford University
    • Year and Date
      20090816-20090819
  • [Presentation] FASEB Summer Research Coference on Histone Deacetylases and Reversible Acetylation in Signaling and Disease2009

    • Author(s)
      Issay Kitabayashi
    • Organizer
      Roles of histone actyltransferase MOZ in hematopoiesis and leukemia
    • Place of Presentation
      Il Ciocco Resort
    • Year and Date
      20090809-20090814
  • [Presentation] USA-Japan Cooperative Cancer Workshop on Stem Cells in Normal and Malignant Hematopoiesis2009

    • Author(s)
      Kitabayashi I.
    • Organizer
      MOZ leukemic stem cells
    • Place of Presentation
      Hilton waikoloa Village in Hawaii, USA
    • Year and Date
      20090327-20090329
  • [Patent(Industrial Property Rights)] (Tharapeutic agent for MLL leukemia and MOZ leukemia of which molecular target is M-CSF receptor, and use thereof2008

    • Inventor(s)
      北林一生
    • Industrial Property Rights Holder
      国立がんセンター総長
    • Industrial Property Number
      PCT・JP2008/072609
    • Filing Date
      2008-12-12
    • Acquisition Date
      2009-06-18
  • [Patent(Industrial Property Rights)] M-CSF受容体を分子標的とするMLL白血病及びMOZ白血病治療剤、およびその利用2007

    • Inventor(s)
      北林一生
    • Industrial Property Rights Holder
      国立がんセンター総長
    • Industrial Property Number
      特願・2007-321256
    • Filing Date
      2007-12-12
    • Acquisition Date
      2007-12-12

URL: 

Published: 2011-06-18   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi